Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Puma Biotechnology (PBYI) EBIAT (2017 - 2025)

Puma Biotechnology's EBIAT history spans 9 years, with the latest figure at $13.4 million for Q4 2025.

  • For Q4 2025, EBIAT fell 30.45% year-over-year to $13.4 million; the TTM value through Dec 2025 reached $31.1 million, up 2.71%, while the annual FY2025 figure was $31.1 million, 2.71% up from the prior year.
  • EBIAT reached $13.4 million in Q4 2025 per PBYI's latest filing, up from $8.8 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $20.3 million in Q3 2024 to a low of -$44.7 million in Q3 2021.
  • Average EBIAT over 5 years is $2.7 million, with a median of $3.6 million recorded in 2021.
  • Peak YoY movement for EBIAT: soared 1710.0% in 2023, then plummeted 443.68% in 2024.
  • A 5-year view of EBIAT shows it stood at $4.2 million in 2021, then crashed by 232.72% to -$5.6 million in 2022, then surged by 318.84% to $12.3 million in 2023, then soared by 57.36% to $19.3 million in 2024, then tumbled by 30.45% to $13.4 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's EBIAT are $13.4 million (Q4 2025), $8.8 million (Q3 2025), and $5.9 million (Q2 2025).